Patrice Boyer1, Cécile Vialet1, Eunhee Hwang1, Karen A Tourian1. 1. University of Ottawa, Ottawa, Canada, and University Paris 7, Paris, France (Dr Boyer); Pfizer Global Research and Development, Paris, France (Ms Vialet); and Pfizer, Collegeville, Pennsylvania (Drs Hwang and Tourian). Dr Tourian is now with inVentiv Health Clinical, Princeton, New Jersey.
Abstract
OBJECTIVE: To examine long-term (11-month) antidepressant efficacy of desvenlafaxine 50 mg/d across a broad range of clinical and functional outcomes in patients with major depressive disorder. METHOD: Adult outpatients (≥ 18 years) with major depressive disorder (DSM-IV criteria) and a 17-item Hamilton Depression Rating Scale (HDRS-17) total score ≥ 20 at screening and baseline who responded to 8 weeks ofopen-label desvenlafaxine50 mg/d and had a continuing stable response through week 20 were randomly assigned to receive placebo or desvenlafaxine 50 mg/d in a 6-month, double-blind, randomized withdrawal period. Depressive symptoms were evaluated using the HDRS-17, 6-item HDRS, and Clinical Global Impressions-Severity of Ilness and -Improvement (CGI-S, CGI-I). Health outcomes included the Work Productivity and Activity Impairment (WPAI) questionnaire and the World Health Organization 5-Item Well-Being Index (WHO-5). The trial was conducted from June 2009 to March 2011 at 87 study sites in 14 countries worldwide. RESULTS: Of 874 patients enrolled in open-label treatment, 548 patients were randomly assigned to receive double-blind placebo (n = 276) or desvenlafaxine 50 mg/d (n = 272). At the end of the 6-month double-blind treatment, improvements in depressive symptoms were better maintained among the desvenlafaxine- than placebo-treated patients on all efficacy endpoints (all P ≤ .001); in the desvenlafaxine group, 21.8% (vs 42.9% in the placebo group) had CGI-I ratings of 5, 6, and 7 (minimally worse/much worse/very much worse), and 74.4% met criteria for remission (placebo: 54.2%). WPAI and WHO-5 scores indicated significantly better productivity and well-being with continued desvenlafaxine (vs placebo, P ≤ .001). CONCLUSIONS: Long-term treatment with desvenlafaxine 50 mg/d maintained improvements in major depressive disorder among adult outpatients who exhibited a stable therapeutic response. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00887224.
RCT Entities:
OBJECTIVE: To examine long-term (11-month) antidepressant efficacy of desvenlafaxine 50 mg/d across a broad range of clinical and functional outcomes in patients with major depressive disorder. METHOD: Adult outpatients (≥ 18 years) with major depressive disorder (DSM-IV criteria) and a 17-item Hamilton Depression Rating Scale (HDRS-17) total score ≥ 20 at screening and baseline who responded to 8 weeks of open-label desvenlafaxine 50 mg/d and had a continuing stable response through week 20 were randomly assigned to receive placebo or desvenlafaxine 50 mg/d in a 6-month, double-blind, randomized withdrawal period. Depressive symptoms were evaluated using the HDRS-17, 6-item HDRS, and Clinical Global Impressions-Severity of Ilness and -Improvement (CGI-S, CGI-I). Health outcomes included the Work Productivity and Activity Impairment (WPAI) questionnaire and the World Health Organization 5-Item Well-Being Index (WHO-5). The trial was conducted from June 2009 to March 2011 at 87 study sites in 14 countries worldwide. RESULTS: Of 874 patients enrolled in open-label treatment, 548 patients were randomly assigned to receive double-blind placebo (n = 276) or desvenlafaxine 50 mg/d (n = 272). At the end of the 6-month double-blind treatment, improvements in depressive symptoms were better maintained among the desvenlafaxine- than placebo-treated patients on all efficacy endpoints (all P ≤ .001); in the desvenlafaxine group, 21.8% (vs 42.9% in the placebo group) had CGI-I ratings of 5, 6, and 7 (minimally worse/much worse/very much worse), and 74.4% met criteria for remission (placebo: 54.2%). WPAI and WHO-5 scores indicated significantly better productivity and well-being with continued desvenlafaxine (vs placebo, P ≤ .001). CONCLUSIONS: Long-term treatment with desvenlafaxine 50 mg/d maintained improvements in major depressive disorder among adult outpatients who exhibited a stable therapeutic response. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00887224.
Authors: David J Nutt; Jonathan R T Davidson; Alan J Gelenberg; Teruhiko Higuchi; Shigenobu Kanba; Oğuz Karamustafalioğlu; George I Papakostas; Kaoru Sakamoto; Takeshi Terao; Mingyuan Zhang Journal: J Clin Psychiatry Date: 2010 Impact factor: 4.384
Authors: L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller Journal: J Affect Disord Date: 1998-09 Impact factor: 4.839
Authors: James H Kocsis; Michael E Thase; Madhukar H Trivedi; Richard C Shelton; Susan G Kornstein; Charles B Nemeroff; Edward S Friedman; Alan J Gelenberg; David L Dunner; Robert M A Hirschfeld; Anthony J Rothschild; James M Ferguson; Alan F Schatzberg; John M Zajecka; Ronald D Pedersen; Bing Yan; Saeed Ahmed; Jeff Musgnung; Philip T Ninan; Martin B Keller Journal: J Clin Psychiatry Date: 2007-07 Impact factor: 4.384
Authors: A A Nierenberg; M M Husain; M H Trivedi; M Fava; D Warden; S R Wisniewski; S Miyahara; A J Rush Journal: Psychol Med Date: 2009-05-22 Impact factor: 7.723
Authors: Robert L Crocker; Jason T Hurwitz; Amy J Grizzle; Ivo Abraham; Rick Rehfeld; Randy Horwitz; Andrew T Weil; Victoria Maizes Journal: Evid Based Complement Alternat Med Date: 2019-06-26 Impact factor: 2.629